Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.

ABSTRACT:

Background

Sunitinib has become mainstay first line treatment for patients with metastatic renal clear cell carcinoma (mRCC). Still, useful predictive markers of response are lacking and urgently needed for clinical decision making.

Methods

In the present study we investigated the predictive value of standard serum markers as well as clinical markers, including C-reactive protein (CRP), Neutrophil to Lymphocyte ratio (NLR) and early hypertension (eHTN) in an unselected prospective patient population treated with sunitinib for mRCC. Forty-six patients were enrolled in a prospective single-arm study of predictive markers for sunitinib response. Response rates according to RECIST 1.1 were used as primary end-point. Secondary objectives were to evaluate prognostic value of the c

SUBMITTER: Pilskog M 

PROVIDER: S-EPMC5580299 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature